San Antonio, TX, Dec 12—Today, investigators of BCRF’s AURORA-US project announced the discovery of key molecular changes between primary tumors and metastases, particularly between Luminal-type tumors and Basal-like tumors.
You are here
The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.
BCRF PRESS RELEASE x
NEW YORK, NY – December 11, 2019 – The Breast Cancer Research Foundation (BCRF) announced $5 million in funding provided by Eli Lilly and Company to conduct investigator-initiated studies of the CDK4 & 6 inhibitor, Verzenio® (abemaciclib).
New York, NY – October 1, 2019 – The Breast Cancer Research Foundation (BCRF) announced its $66 million commitment to fund breast cancer research for 2019-2020.
Breast cancer mortality is at its lowest level in 30 years. This success has largely been fueled by advances in early detection and treatment.
May 6, 2019, New York, NY—Today, the Breast Cancer Research Foundation (BCRF) announced that breast cancer researcher Dorraya El-Ashry, PhD, joined its executive leadership team as Chief Scientific Officer. Dr.
New York, NY – October 1, 2018 – The Breast Cancer Research Foundation (BCRF) today announced a record-breaking $63 million commitment to fund breast cancer research for 2018-2019.
NEW YORK, NY – FEB 2, 2018– Ahead of World Cancer Day, the Breast Cancer Research Foundation (BCRF) announced a new, independent research project funded by grants from Astellas and Pfizer to advance understanding of the role of the androgen receptor in breast cancer.
PRESS RELEASE: New York, NY – October 2, 2017 – The Breast Cancer Research Foundation (BCRF) today announced a $59.5 million commitment to breast cancer research for 2017-2018.
NEW YORK, NY---(JULY 18, 2017)--- The Estée Lauder Companies’ Breast Cancer Campaign has announced its Title Sponsorship of Play for P.I.N.K.
March 14, 2017 – The Jayne Koskinas Ted Giovanis (JKTG) Foundation for Health and Policy and the Breast Cancer Research Foundation (BCRF) are jointly funding three multi-institutional collaborations with projects that have the potential to substantially advance understanding of cancer biology or